CN111542531B - 取代的核苷、核苷酸以及它们的类似物 - Google Patents

取代的核苷、核苷酸以及它们的类似物 Download PDF

Info

Publication number
CN111542531B
CN111542531B CN201880074579.2A CN201880074579A CN111542531B CN 111542531 B CN111542531 B CN 111542531B CN 201880074579 A CN201880074579 A CN 201880074579A CN 111542531 B CN111542531 B CN 111542531B
Authority
CN
China
Prior art keywords
compound
virus
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880074579.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111542531A (zh
Inventor
L.贝格曼
J.德瓦尔
M.普哈斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jensen Biopharmaceutical Co ltd
Original Assignee
Jensen Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jensen Biopharmaceutical Co ltd filed Critical Jensen Biopharmaceutical Co ltd
Publication of CN111542531A publication Critical patent/CN111542531A/zh
Application granted granted Critical
Publication of CN111542531B publication Critical patent/CN111542531B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880074579.2A 2017-09-18 2018-09-18 取代的核苷、核苷酸以及它们的类似物 Active CN111542531B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560110P 2017-09-18 2017-09-18
US62/560110 2017-09-18
PCT/IB2018/057188 WO2019053696A1 (en) 2017-09-18 2018-09-18 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Publications (2)

Publication Number Publication Date
CN111542531A CN111542531A (zh) 2020-08-14
CN111542531B true CN111542531B (zh) 2024-07-19

Family

ID=63794555

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880074579.2A Active CN111542531B (zh) 2017-09-18 2018-09-18 取代的核苷、核苷酸以及它们的类似物

Country Status (17)

Country Link
US (2) US11149049B2 (https=)
EP (1) EP3684782A1 (https=)
JP (1) JP2020534361A (https=)
KR (1) KR102696517B1 (https=)
CN (1) CN111542531B (https=)
AU (1) AU2018332540B2 (https=)
CA (1) CA3075950A1 (https=)
CL (1) CL2020000685A1 (https=)
CR (1) CR20200126A (https=)
EA (1) EA202090775A1 (https=)
EC (1) ECSP20022130A (https=)
IL (1) IL273341A (https=)
MA (1) MA50172A (https=)
MX (1) MX2020002925A (https=)
PH (1) PH12020550114A1 (https=)
SG (1) SG11202002295QA (https=)
WO (1) WO2019053696A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209983A1 (en) 2013-06-26 2014-12-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
CR20200126A (es) * 2017-09-18 2020-07-11 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos
EP3946611A2 (en) 2019-03-31 2022-02-09 Yeda Research and Development Co. Ltd Anti-viral and anti-tumoral compounds
CN110724174B (zh) * 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
CN110776512A (zh) * 2019-11-28 2020-02-11 成都傲飞生物化学品有限责任公司 一种核苷类似物的制备方法
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) * 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI775313B (zh) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CN113292565B (zh) * 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
CN113387954B (zh) * 2020-03-11 2024-03-19 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN111961057A (zh) * 2020-05-26 2020-11-20 李小冬 一种α构型核苷及其在治疗猫冠状病毒感染的应用
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
AU2021296841B2 (en) * 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
MX2023001002A (es) 2020-07-24 2023-03-01 Univ California Farmacos antivirales, composiciones farmaceuticas, y metodos.
WO2022038539A2 (en) * 2020-08-18 2022-02-24 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
AU2021330835B2 (en) 2020-08-24 2023-12-14 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
SI4204421T1 (sl) * 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
JP2023541960A (ja) * 2020-09-17 2023-10-04 メレティオス セラピューティクス ウイルス感染を治療するための化合物
CN112142810A (zh) * 2020-09-29 2020-12-29 佛山科学技术学院 核苷酸双氨基磷酸酯化合物、其药物组合物及其制备方法和应用
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN114588159A (zh) * 2020-12-07 2022-06-07 成都傲科新技术有限责任公司 一种治疗猫冠状病毒感染的化合物及其应用
CN114634529A (zh) * 2020-12-15 2022-06-17 中国科学院大连化学物理研究所 一种氟代瑞德西韦及其合成方法
JP2024503755A (ja) * 2020-12-30 2024-01-26 サウザン・ユニバーシティ・オブ・サイエンス・アンド・テクノロジー ウイルス感染症治療用ヌクレオシド系化合物及びその用途
US12558364B2 (en) 2021-01-20 2026-02-24 Regents Of The University Of Minnesota Next generation remdesivir antivirals
WO2022166581A1 (zh) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
US20240166680A1 (en) * 2021-04-15 2024-05-23 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nucleoside analog and use thereof
EP4323362B1 (en) * 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
EP4323361A1 (en) * 2021-04-16 2024-02-21 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
IL310854A (en) * 2021-08-20 2024-04-01 Shionogi & Co Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity
CN118591377A (zh) 2022-01-26 2024-09-03 加利福尼亚大学董事会 抗病毒前药、中效和长效制剂和方法
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
PE20250419A1 (es) * 2022-03-03 2025-02-14 Gilead Sciences Inc Compuestos antivirales y metodos de elaboracion y uso de los mismos
CN114573590B (zh) * 2022-03-18 2023-11-14 苏州旺山旺水生物医药有限公司 一种四异丁酰基核苷类似物的制备方法及用途
CN116891474A (zh) * 2022-03-31 2023-10-17 苏州旺山旺水生物医药有限公司 一种单异丁酰基核苷类似物的制备方法
WO2024002112A1 (zh) * 2022-06-28 2024-01-04 苏州旺山旺水生物医药股份有限公司 一种治疗猫冠状或杯状病毒感染的方法
CN115894498A (zh) * 2022-10-01 2023-04-04 海化生命(厦门)科技有限公司 一种潜在抗病毒药物中间体bl及其合成方法
CN120152976A (zh) * 2022-10-23 2025-06-13 上海柯君医药科技有限公司 抗冠状病毒化合物及其组合物和用途
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
US20250090537A1 (en) * 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
CN117509571B (zh) * 2023-11-01 2025-12-05 乐威医药（江苏）股份有限公司 一种连续化制备叠氮化碘的方法及其应用
CN118304315B (zh) * 2024-04-12 2025-03-25 深圳安泰维生物医药有限公司 一种核苷类化合物在制备抗呼吸道合胞病毒感染相关产品上的用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015714A (zh) * 2008-04-23 2011-04-13 吉里德科学公司 用于抗病毒治疗的1’-取代的carba-核苷类似物
CN103052631A (zh) * 2010-07-22 2013-04-17 吉里德科学公司 用于治疗副黏病毒科病毒感染的方法和化合物
CN103209987A (zh) * 2010-09-22 2013-07-17 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
CN105829333A (zh) * 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
WO2017049060A1 (en) * 2015-09-16 2017-03-23 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
CN106573011A (zh) * 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
CN106795199A (zh) * 2014-03-28 2017-05-31 默沙东公司 作为hiv逆转录酶抑制剂的4’‑取代的核苷衍生物
CN107073005A (zh) * 2014-10-29 2017-08-18 吉利德科学公司 治疗丝状病毒科病毒感染的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2005020884A2 (en) 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
AU2013216595B2 (en) * 2008-04-23 2016-07-28 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
PE20120995A1 (es) * 2009-09-21 2012-08-01 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
EP2619215B1 (en) * 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
AU2011349278C1 (en) * 2010-12-22 2017-01-19 Alios Biopharma, Inc. Cyclic nucleotide analogs
EP2794630A4 (en) * 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
TN2016000566A1 (en) * 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CR20200126A (es) * 2017-09-18 2020-07-11 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015714A (zh) * 2008-04-23 2011-04-13 吉里德科学公司 用于抗病毒治疗的1’-取代的carba-核苷类似物
CN103052631A (zh) * 2010-07-22 2013-04-17 吉里德科学公司 用于治疗副黏病毒科病毒感染的方法和化合物
CN105343098A (zh) * 2010-07-22 2016-02-24 吉里德科学公司 用于治疗副黏病毒科病毒感染的方法和化合物
CN103209987A (zh) * 2010-09-22 2013-07-17 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
CN105829333A (zh) * 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
CN106795199A (zh) * 2014-03-28 2017-05-31 默沙东公司 作为hiv逆转录酶抑制剂的4’‑取代的核苷衍生物
CN106573011A (zh) * 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
CN107073005A (zh) * 2014-10-29 2017-08-18 吉利德科学公司 治疗丝状病毒科病毒感染的方法
WO2017049060A1 (en) * 2015-09-16 2017-03-23 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections

Also Published As

Publication number Publication date
KR20200098483A (ko) 2020-08-20
IL273341A (en) 2020-05-31
SG11202002295QA (en) 2020-04-29
EP3684782A1 (en) 2020-07-29
ECSP20022130A (es) 2020-07-31
US20210395288A1 (en) 2021-12-23
EA202090775A1 (ru) 2020-07-06
BR112020005177A2 (pt) 2020-09-15
MX2020002925A (es) 2020-10-05
CR20200126A (es) 2020-07-11
AU2018332540A1 (en) 2020-04-30
WO2019053696A1 (en) 2019-03-21
KR102696517B1 (ko) 2024-08-21
CA3075950A1 (en) 2019-03-21
CL2020000685A1 (es) 2020-10-23
US11149049B2 (en) 2021-10-19
US11773126B2 (en) 2023-10-03
US20200277321A1 (en) 2020-09-03
CN111542531A (zh) 2020-08-14
AU2018332540B2 (en) 2023-10-05
JP2020534361A (ja) 2020-11-26
PH12020550114A1 (en) 2020-12-07
MA50172A (fr) 2021-04-07

Similar Documents

Publication Publication Date Title
CN111542531B (zh) 取代的核苷、核苷酸以及它们的类似物
CA2927010C (en) Substituted nucleosides, nucleotides and analogs thereof
US20190169221A1 (en) Substituted nucleosides, nucleotides and analogs thereof
AU2011349278B2 (en) Cyclic nucleotide analogs
US9890188B2 (en) Substituted nucleosides, nucleotides and analogs thereof
CN107250146A (zh) 取代的核苷、核苷酸及其类似物
CA2952966A1 (en) Substituted nucleosides, nucleotides and analogs thereof
HK1216254A1 (zh) 取代的核苷酸類似物
TW201333028A (zh) 經取代的核苷酸類似物
BG108000A (bg) Н"кл...озидни производни, използвани ка'о инхиби'ори на зави'има о' рнк, рнк вир"'на полим...раза
RS61767B1 (sr) 4'-fluor-nukleozidi, 4'-fluor-nukleotidi i njihovi analozi za lečenje hcv
BR112020005177B1 (pt) Compostos análogos de nucleotídeos substituídos, seus usos, e composição farmacêutica
EA042416B1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
OA19518A (en) Substituted nucleosides, nucleotides and analogs thereof.
KR20260016917A (ko) 항바이러스제로서의 4'-치환 뉴클레오사이드 및 뉴클레오타이드
HK1187350A (zh) 取代的核苷酸類似物
TW201215395A (en) Substituted nucleotide analogs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant